Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 23Leukemia 13Leukemia, Myeloid, Chronic-Phase 11Gastrointestinal Stromal Tumors 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 4Neoplasms 3Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myeloid 3Blast Crisis 3Thyroid Neoplasms 2Prostatic Neoplasms 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Bone Marrow Diseases 2Uterine Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

Cyclophosphamide 4Rituximab 3cobomarsen 2Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2thymoglobulin 1ponatinib 1ibritumomab tiuxetan 1fludarabine phosphate 1fludarabine 1Vorinostat 1Tacrolimus 1Mycophenolic Acid 1Melphalan 1Imatinib Mesylate 1Ifosfamide 1Cytarabine 1Carmustine 1Carboplatin 1Busulfan 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Immune System Diseases × Imatinib Mesylate × Clear all
NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡